- Home
- BMBL vs PRTA Comparison
BMBL vs PRTA Comparison
Compare BMBL & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMBL
- PRTA
- Stock Information
- Founded
- BMBL 2014
- PRTA 2012
- Country
- BMBL United States
- PRTA Ireland
- Employees
- BMBL N/A
- PRTA N/A
- Industry
- BMBL Computer Software: Prepackaged Software
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- BMBL Technology
- PRTA Health Care
- Exchange
- BMBL Nasdaq
- PRTA Nasdaq
- Market Cap
- BMBL 828.7M
- PRTA 765.2M
- IPO Year
- BMBL 2021
- PRTA N/A
- Fundamental
- Price
- BMBL $5.21
- PRTA $15.56
- Analyst Decision
- BMBL Hold
- PRTA Buy
- Analyst Count
- BMBL 17
- PRTA 8
- Target Price
- BMBL $7.91
- PRTA $46.00
- AVG Volume (30 Days)
- BMBL 3.7M
- PRTA 336.3K
- Earning Date
- BMBL 02-18-2025
- PRTA 02-20-2025
- Dividend Yield
- BMBL N/A
- PRTA N/A
- EPS Growth
- BMBL N/A
- PRTA N/A
- EPS
- BMBL N/A
- PRTA N/A
- Revenue
- BMBL $1,083,632,000.00
- PRTA $135,157,000.00
- Revenue This Year
- BMBL $3.82
- PRTA $56.89
- Revenue Next Year
- BMBL N/A
- PRTA N/A
- P/E Ratio
- BMBL N/A
- PRTA N/A
- Revenue Growth
- BMBL 6.26
- PRTA 47.92
- 52 Week Low
- BMBL $4.80
- PRTA $11.70
- 52 Week High
- BMBL $13.37
- PRTA $31.03
- Technical
- Relative Strength Index (RSI)
- BMBL 22.02
- PRTA 59.65
- Support Level
- BMBL $8.20
- PRTA $13.69
- Resistance Level
- BMBL $8.64
- PRTA $15.09
- Average True Range (ATR)
- BMBL 0.41
- PRTA 0.91
- MACD
- BMBL -0.36
- PRTA 0.13
- Stochastic Oscillator
- BMBL 0.82
- PRTA 68.56
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).